Update on the 5-FU Trial
The current phase 0/1 study using the drug called 5-Fluorouracil (5-FU) is now closed to accrual. This trial was open at St. Jude Children’s Research Hospital. The results are undergoing analysis. The goals of this study were first to determine the optimal dose and treatment schedule of the medication to get it past the blood-brain barrier and into the tumor. While drugs like 5-FU have been used for a long time and in certain ways, their effectiveness can be dramatically different if one changes the way they are given. The best dose is often referred to as the maximum tolerated dose (MTD). In treating cancer, the goal is to give the maximum dose to treat the tumor with tolerable side effects. The phase 0/1 study is complete and a MTD established. Those results will be compiled and submitted for publication in the upcoming months.
Now that phase 0/1 is complete, we are determining how best to integrate 5-FU in a protocol that will treat newly diagnosed ependymoma patients. We envision that this study will treat the ependymoma patients according to molecular and clinical features that have been described recently in laboratory funded research by the CERN Foundation. We anticipate that this study will be available for patient enrollment towards the last quarter of 2015 at pediatric CERN sites.
Find out more information about the phases of clinical trials and the 5-FU trial.
If you have questions about this trial or any of our trials, contact us. CERN remains committed to finding new treatments for ependymoma, improving patients’ lives, and ultimately finding a cure.